Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Trevena Inc    TRVN

TREVENA INC (TRVN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Trevena : Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Are Encouraged to Contact The Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/11/2018 | 08:45pm CEST

BOSTON, Oct. 11, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, announces that it has filed a securities fraud class action against Trevena, Inc. ("Trevena" or the "Company") (NASDAQ: TRVN) and certain of its officers alleging violations of the federal securities laws and encourages shareholders to contact Block & Leviton ahead of the December 10, 2018 lead plaintiff deadline.

The complaint, filed in the United States District Court Eastern District of Pennsylvania, captioned Tomaszewski v. Trevena, Inc. et al., Case No. 2:18-cv-04378, alleges that between May 2, 2016 and October 8, 2018, inclusive (the "Class Period"), Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Trevena misled its shareholders to believe that its April 28, 2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration ("FDA") was far more successful than it actually was. The Company did so by issuing a press release entitled "Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine," on May 2, 2016, in which it announced that it had "reached general agreement" with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was "very pleased" with the outcome of its discussions with the FDA. In fact, FDA minutes from its April 28, 2016 meeting with the Company show that the FDA:

  • "did not agree with the proposed dosing in the Phase 3 studies";
  • "did not agree with the proposed primary endpoint"; and
  • "did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine"

As a result of Defendants' wrongful acts and omissions, and the precipitous decline in the market value of the Company's securities, Plaintiff and other Class Members have suffered significant losses and damages.

If you purchased TRVN shares between May 2, 2016 and October 8, 2018 and wish to serve as a lead plaintiff, you must move the Court no later than December 10, 2018.

If you wish to become involved in the litigation or have questions about your legal rights, you are encouraged to contact attorneys John DeFelice or Jake Walker at (888) 868-2385, by email at john@blockesq.com or jake@blockesq.com, or by visiting http://shareholder.law/trevena.

Confidentiality to whistleblowers or others with information relevant to this investigation is assured.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

The court in which this case is pending is located at 601 Market Street, Philadelphia, PA 19106.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110
john@blockesq.com

 

Cision View original content:http://www.prnewswire.com/news-releases/block--leviton-files-securities-class-action-against-trevena-inc-trvn-investors-are-encouraged-to-contact-the-firm-300729794.html

SOURCE Block & Leviton LLP


© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TREVENA INC
10/15IMPORTANT INVESTOR REMINDER : The Schall Law Firm Announces the Filing of a Clas..
BU
10/15LAW OFFICES OF HOWARD G. SMITH : Announces the Filing of a Securities Class Acti..
BU
10/13IMPORTANT INVESTOR NOTICE : The Schall Law Firm Announces the Filing of a Class ..
BU
10/12ROBBINS ARROYO LLP : Trevena, Inc. (TRVN) Misled Shareholders According to a Cla..
BU
10/12Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the Ame..
GL
10/12SHAREHOLDER ALERT - BRONSTEIN, GEWIR : December 10, 2018
PR
10/12TREVENA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/12TREVENA : Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for..
AQ
10/12TREVENA : Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Tre..
AQ
10/12TREVENA : Advisory panel narrowly rejects oliceridine for acute pain
AQ
More news
News from SeekingAlpha
10/15YOUR DAILY PHARMA SCOOP : AcelRx, How Far Can It Go; Trevena's Future 
10/12Trevena down 13% premarket after negative Ad Com vote 
10/11Ad Com thumbs down on Trevena's oliceridine 
10/11Avenue Therapeutics up 95% on dim Ad Com prospects for Trevena's oliceridine 
10/11Trevene discloses disagreement with FDA over Phase 3 endpoints for oliceridin..